In October 2021 it was announed that Cernostics had been acquired by Texas based Castle Biosciences (NASDAQ.CSTL) - a biotech company structured around development of diagnostic tests and technologies employed incancer reatment. Cernostics Pathology Inc. is a diagnostics company focused on developing cancer diagnostics and prognostics using a proprietary technology for tissue analysis. The company's technology is based on a tissue systems biology approach in which a tumor is evaluated as a system composed of multiple interacting cell types. The company's TissueCypher⢠technology uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Cernostics' lead product is TissueCypher⢠Barrett's Esophagus Assay, which is focused on eliminating the uncertainty related to the treatment of Barrett's Esophagus patients and providisng actionable information to gastroenterologist
